Table 2.
Baseline characteristics of patients without a COVID-19 history according to seronversion status after COVID-19 vaccination
| Variable | Early responder group | Late responder group | Non-responder group | P-value |
|---|---|---|---|---|
| Age (years), mean (SD) | 64.4 (3.6) | 70 (2.1) | 73.5 (3.2) | 0.17 |
| Male, n (%) | 7 (53.9) | 24 (63.2) | 9 (56.3) | 0.8 |
| BMI (kg/m2), mean (SD) | 27.8 (1.6) | 26 (1) | 24 (1.4) | 0.2 |
| DN and/or nephroangioslcerosis, n (%) | 4 (30.8) | 9 (23.7) | 5(31.3) | 0.5 |
| Glomerulonephritis, n (%) | 5 (38.5) | 16 (42.1) | 7 (43.8) | |
| Autosomal dominant polycystic kidney disease, n (%) | 0 | 0 | 0 | |
| Tubulo-interstitial nephropathy, n (%) | 3 (23.1) | 9 (23.7) | 3 (18.8) | |
| Indeterminate nephropathy, n (%) | 1 (7.7) | 4 (10.5) | 1 (6.3) | |
| Blood group, n (%) | 0.6 | |||
| O | 6 (46.2) | 19 (51.4) | 9 (56.3) | |
| A | 6 (46.2) | 11 (29.7) | 7 (43.8) | |
| B | 1 (7.7) | 6 (16.2) | 0 | |
| AB, missing value (n = 2) | 0 | 1 (2.7) | 0 | |
| Dialysis vintage (years), mean (SD) | 6 (2.6) | 6.7 (1.5) | 4.8 (2.4) | 0.8 |
| On steroids and/or immunosuppressants, n (%) | 0 | 3 (7.9) | 4 (25) | 0.07 |
| Diabetes, n (%) | 5 (38.5) | 19 (50) | 5 (31.3) | 0.4 |
| Chronic respiratory disease, n (%) | 3 (23.1) | 18 (47.4) | 2 (12.5) | 0.03 |
| Arterial hypertension, n (%) | 11 (84.6) | 33 (86.8) | 13 (81.3) | 0.9 |
| Ischaemic cardiac disease, n (%) | 3 (23.1) | 14 (36.8) | 11 (68.8) | 0.03 |
| Rhythmic cardiac disease, n (%) | 2 (15.4) | 7 (18.4) | 6 (37.5) | 0.2 |
| Stroke, n (%) | 3 (23.1) | 8 (21.1) | 4 (25) | 0.9 |
| Peripheral artery disease, n (%) | 2 (15.4) | 12 (31.6) | 5 (31.3) | 0.5 |
| Cirrhosis, n (%) | 0 | 1(2.6) | 3 (18.8) | 0.04 |
| History of or active cancer/transplantation, n (%) | 3 (23.1) | 10 (26.3) | 10 (62.5) | 0.02 |
| Albumin (g/L), mean (SD) | 36.1 (1.1) | 36 (0.7) | 34 (1.1) | 0.2 |
| Gamma globulin (g/L), mean (SD) | 11.1 (0.8) | 9.1 (0.5) | 7.3 (0.8) | 0.006 |
| Lymphocyte count (×109/L), mean (SD) | 1.2 (0.2) | 1.2 (0.1) | 1.5 (0.2) | 0.6 |
| Pre-dialysis β2-microglobulinaemia (mg/L), mean (SD) | 28.2 (1.7) | 28 (1) | 27 (1.6) | 0.9 |
| C-reactive protein (mg/L), mean (SD) | 10.3 (4.4) | 13.9 (2.6) | 9.6 (4) | 0.6 |
| HBV vaccine responders, n (%) | 5 (38.5) | 14 (36.8) | 4 (25) | 0.7 |